Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows

Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows
Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, results of a Phase 3 trial show. The benefits were seen across multiple patient subgroups, regardless of initial tumor volume, pattern of disease location, geographic region, and prior use of Taxotere (docetaxel), researchers said. Findings from the ARCHES Phase 3 trial (NCT02677896) were recently presented at the 2019 Genitourinary Cancers Symposium in San Francisco, California. Xtandi, developed by Pfizer and Astellas, is an approved treatment for men whose prostate cancer no longer responds to medical or surgical treatment — a condition called castration-resistant prostate cancer. The treatment is approved for men with metastatic and non-metastatic disease, based on clinical data from two Phase 3 trials — LATITUDE (NCT01715285) and PROSPER<
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *